$NVAX
NOVAVAX INC Stock $nvax

$nvax Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000100069424000031 Filed on May 10, 2024

Income Statement

Concept	2024 Q2	2024 Q1
Revenue	$415.5M	$93.86M
YoY Change	-2.11%	15.94%
Cost Of Revenue	$46.24M	$59.21M
YoY Change	-17.09%	73.7%
Gross Profit	$369.2M	$34.65M
YoY Change	0.16%	-26.07%
Gross Profit Margin	88.87%	36.91%
Selling, General & Admin	$101.0M	$86.80M
YoY Change	22.84%	-22.87%
% of Gross Profit	27.35%	250.53%
Research & Development	$106.9M	$92.68M
YoY Change	-51.27%	-62.49%
% of Gross Profit	28.96%	267.5%
Depreciation & Amortization	$11.13M	$12.15M
YoY Change	10.58%	34.32%
% of Gross Profit	3.01%	35.06%
Operating Expenses	$106.9M	$92.68M
YoY Change	-51.27%	-62.49%
Operating Profit	$161.0M	-$144.8M
YoY Change	190.31%	-53.69%
Interest Expense	-$4.143M	$4.111M
YoY Change	-232.62%	-4.75%
% of Operating Profit	-2.57%
Other Income/Expense, Net	$7.731M	$3.654M
YoY Change	39.75%	-85.0%
Pretax Income	$164.6M	-$145.3M
YoY Change	184.43%	-50.37%
Income Tax	$2.205M	$2.262M
% Of Pretax Income	1.34%
Net Earnings	$162.4M	-$147.6M
YoY Change	179.93%	-49.8%
Net Earnings / Revenue	39.08%	-157.21%
Basic Earnings Per Share	$1.09	-$1.05
Diluted Earnings Per Share	$0.99	-$1.05
COMMON SHARES
Basic Shares Outstanding	140.4M shares	140.0M shares
Diluted Shares Outstanding	165.9M shares	139.9M shares

Balance Sheet

Concept	2024 Q2	2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.050B	$480.6M
YoY Change	107.47%	-23.1%
Cash & Equivalents	$680.2M	$480.6M
Short-Term Investments	$369.4M
Other Short-Term Assets	$112.5M	$209.4M
YoY Change	-44.65%	5.19%
Inventory	$9.172M	$15.78M
Prepaid Expenses
Receivables	$32.10M	$21.38M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$1.203B	$727.1M
YoY Change	6.72%	-25.12%
LONG-TERM ASSETS
Property, Plant & Equipment	$288.6M	$291.1M
YoY Change	-3.8%	-5.31%
Goodwill	$123.4M	$123.2M
YoY Change	-3.89%	-5.12%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$33.83M	$30.97M
YoY Change	1.19%	1.51%
Total Long-Term Assets	$615.3M	$626.4M
YoY Change	10.36%	9.58%
TOTAL ASSETS
Total Short-Term Assets	$1.203B	$727.1M
Total Long-Term Assets	$615.3M	$626.4M
Total Assets	$1.819B	$1.354B
YoY Change	7.93%	-12.26%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$79.96M	$57.72M
YoY Change	-8.35%	-53.75%
Accrued Expenses	$159.2M	$257.4M
YoY Change	-65.27%	-50.38%
Deferred Revenue	$666.4M	$240.9M
YoY Change	121.78%	-42.06%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$9.427M	$6.291M
YoY Change	889.19%	422.07%
Total Short-Term Liabilities	$1.158B	$804.4M
YoY Change	-27.47%	-58.08%
LONG-TERM LIABILITIES
Long-Term Debt	$223.8M	$223.0M
YoY Change	13.04%	12.73%
Other Long-Term Liabilities	$335.3M	$351.7M
YoY Change	773.54%	640.3%
Total Long-Term Liabilities	$335.3M	$351.7M
YoY Change	773.54%	640.3%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.158B	$804.4M
Total Long-Term Liabilities	$335.3M	$351.7M
Total Liabilities	$2.250B	$2.221B
YoY Change	-7.76%	-8.93%
SHAREHOLDERS EQUITY
Retained Earnings	-$4.806B	-$4.969B
YoY Change	6.52%	8.72%
Common Stock	$1.613M	$1.417M
YoY Change	69.43%	62.69%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$431.7M	-$867.1M
YoY Change
Total Liabilities & Shareholders Equity	$1.819B	$1.354B
YoY Change	7.93%	-12.26%

Cashflow Statement

Concept	2024 Q2	2024 Q1
OPERATING ACTIVITIES
Net Income	$162.4M	-$147.6M
YoY Change	179.93%	-49.8%
Depreciation, Depletion And Amortization	$11.13M	$12.15M
YoY Change	10.58%	34.32%
Cash From Operating Activities	$314.3M	-$83.60M
YoY Change	-282.78%	-74.32%
INVESTING ACTIVITIES
Capital Expenditures	$2.875M	$6.878M
YoY Change	-58.77%	-65.26%
Acquisitions
YoY Change
Other Investing Activities	-$369.8M	-$372.0K
YoY Change	45784.86%	-90.1%
Cash From Investing Activities	-$372.7M	-$7.250M
YoY Change	4691.19%	-69.22%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	258.2M	$5.886M
YoY Change	320.99%	-101.66%
NET CHANGE
Cash From Operating Activities	314.3M	-$83.60M
Cash From Investing Activities	-372.7M	-$7.250M
Cash From Financing Activities	258.2M	$5.886M
Net Change In Cash	199.8M	-$87.87M
YoY Change	-268.76%	-87.66%
FREE CASH FLOW
Cash From Operating Activities	$314.3M	-$83.60M
Capital Expenditures	$2.875M	$6.878M
Free Cash Flow	$311.4M	-$90.48M
YoY Change	-274.05%	-73.8%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	305771000	usd
CY2024Q1	nvax	Lease Right Of Use Asset LeaseRightOfUseAsset	181175000	usd
CY2023Q4	nvax	Lease Right Of Use Asset LeaseRightOfUseAsset	185218000	usd
CY2024Q1	us-gaap	Revenues Revenues	93855000	usd
CY2023Q1	us-gaap	Revenues Revenues	80951000	usd
CY2024Q1	us-gaap	Cost Of Revenue CostOfRevenue	59209000	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	34086000	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	92679000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	247101000	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	86798000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	112532000	usd
CY2024Q1	us-gaap	Costs And Expenses CostsAndExpenses	238686000	usd
CY2023Q1	us-gaap	Costs And Expenses CostsAndExpenses	393719000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-144831000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-312768000	usd
CY2024Q1	us-gaap	Interest Expense InterestExpense	4111000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	4316000	usd
CY2024Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3654000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	24362000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-145288000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-292722000	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2262000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1183000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-147550000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-293905000	usd
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.05
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.05
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.41
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.41
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	139916000	shares
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	139916000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	86158000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	86158000	shares
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-147550000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-293905000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-13547000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	3211000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-13547000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	3211000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-161097000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-290694000	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	480586000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	568505000	usd
CY2024Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	10455000	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	10424000	usd
CY2024Q1	us-gaap	Accounts Receivable Net AccountsReceivableNet	21380000	usd
CY2023Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	297240000	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	15778000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	41696000	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	198921000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	226023000	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	727120000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	1143888000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	291093000	usd
CY2024Q1	us-gaap	Goodwill Goodwill	123179000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	127454000	usd
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	30967000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	35159000	usd
CY2024Q1	us-gaap	Assets Assets	1353534000	usd
CY2023Q4	us-gaap	Assets Assets	1797490000	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	57724000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	132610000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	257365000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	394668000	usd
CY2024Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	240900000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	241310000	usd
CY2024Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	6291000	usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	5142000	usd
CY2024Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	242102000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	861408000	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	804382000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1635138000	usd
CY2024Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	841473000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	622210000	usd
CY2024Q1	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	168432000	usd
CY2023Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	168016000	usd
CY2024Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	54609000	usd
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	55923000	usd
CY2024Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	351722000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	33130000	usd
CY2024Q1	us-gaap	Liabilities Liabilities	2220618000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	2514417000	usd
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	600000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	600000000	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	141700972	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	140373255	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	140506093	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	139505770	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	1417000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	1405000	usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	4204775000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	4192164000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-4968501000	usd
CY2024Q1	nvax	Net Proceeds From The Exercise Of Stock Based Awards NetProceedsFromTheExerciseOfStockBasedAwards	-616000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-4820951000	usd
CY2024Q1	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	1327717	shares
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	1000323	shares
CY2024Q1	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	93950000	usd
CY2023Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	92267000	usd
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-10825000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	2722000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-867084000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-716927000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1353534000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1797490000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-716927000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	11556000	usd
CY2024Q1	nvax	Compensation Stock Issued Under Incentive Program CompensationStockIssuedUnderIncentiveProgram	-616000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-13547000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-147550000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-867084000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-634078000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	28647000	usd
CY2023Q1	nvax	Compensation Stock Issued Under Incentive Program CompensationStockIssuedUnderIncentiveProgram	543000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	3211000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-293905000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-895582000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-147550000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-293905000	usd
CY2024Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	12147000	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	9043000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	11556000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	28647000	usd
CY2024Q1	nvax	Provision For Excess And Obsolete Inventory ProvisionForExcessAndObsoleteInventory	8807000	usd
CY2023Q1	nvax	Provision For Excess And Obsolete Inventory ProvisionForExcessAndObsoleteInventory	12490000	usd
CY2024Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	1669000	usd
CY2023Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2024Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	4449000	usd
CY2023Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	1252000	usd
CY2024Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-16819000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	9222000	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-296054000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-18430000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-272461000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-230099000	usd
CY2024Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-6147000	usd
CY2023Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	140275000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-83555000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-325593000	usd
CY2024Q1	us-gaap	Payments For Capital Improvements PaymentsForCapitalImprovements	6878000	usd
CY2023Q1	us-gaap	Payments For Capital Improvements PaymentsForCapitalImprovements	19801000	usd
CY2024Q1	us-gaap	Payments For Software PaymentsForSoftware	372000	usd
CY2023Q1	us-gaap	Payments For Software PaymentsForSoftware	3757000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-7250000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-23558000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6862000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2023Q1	nvax	Net Proceeds From The Exercise Of Stock Based Awards NetProceedsFromTheExerciseOfStockBasedAwards	543000	usd
CY2024Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	360000	usd
CY2023Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	26331000	usd
CY2024Q1	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0	usd
CY2023Q1	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	325000000	usd
CY2024Q1	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	0	usd
CY2023Q1	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	3591000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5886000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-354379000	usd
CY2024Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-2955000	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-8372000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-87874000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-711902000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	583810000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1348845000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	495936000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	636943000	usd
CY2024Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1208000	usd
CY2023Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	10847000	usd
CY2024Q1	nvax	Internal Use Software Included In Accounts Payable And Accrued Expenses InternalUseSoftwareIncludedInAccountsPayableAndAccruedExpenses	250000	usd
CY2023Q1	nvax	Internal Use Software Included In Accounts Payable And Accrued Expenses InternalUseSoftwareIncludedInAccountsPayableAndAccruedExpenses	0	usd
CY2024Q1	us-gaap	Interest Paid Net InterestPaidNet	1206000	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	6566000	usd
CY2024Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-71000	usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2024Q1	us-gaap	Nature Of Operations NatureOfOperations	Organization and Business<div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Novavax, Inc. (“Novavax,” and together with its wholly owned subsidiaries, the “Company”) is a biotechnology company that promotes improved health by discovering, developing, and commercializing innovative vaccines to prevent serious infectious diseases. Novavax offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and patented Matrix-M™ adjuvant to enhance the immune response. Novavax currently has one commercial program, for vaccines to prevent COVID-19, which includes Nuvaxovid™ prototype COVID-19 vaccine ("NVX-CoV2373,” or “prototype vaccine”) and Nuvaxovid™ updated COVID-19 vaccine (“NVX-CoV2601,” or “updated vaccine”) (collectively, “COVID-19 Vaccine”). Local regulatory authorities have also specified nomenclature for the labeling of the prototype and updated vaccines within their territories (e.g., “Novavax COVID-19 Vaccine, Adjuvanted” and “Novavax COVID-19, Adjuvanted (2023-2024 Formula),” respectively, for the U.S.). The Company’s partner, Serum Institute of India Pvt. Ltd. (“SIIPL”), markets NVX-CoV2373 as “Covovax™.” </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2022, the Company received approval, interim authorization, provisional approval, conditional marketing authorization, and emergency use authorization (“EUA”) from multiple regulatory authorities globally for its prototype vaccine for both adult and adolescent populations as a primary series and for both homologous and heterologous booster indications in select territories. In October 2023, the U.S. Food and Drug Administration amended the EUA for its prototype vaccine to include its updated vaccine. The amended EUA authorizes use of the Company’s updated vaccine in individuals 12 years and older. In October 2023, the European Commission (“EC”) granted approval for the Company’s updated vaccine for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals aged 12 and older. Currently, the Company significantly depends on its supply agreement with SIIPL and its subsidiary, Serum Life Sciences Limited (“SLS”), for co-formulation, filling and finishing (other than in Europe) and on its service agreement with PCI Pharma Services for finishing in Europe. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Novavax is advancing development of other vaccine candidates, including its COVID-19-Influenza Combination (“CIC”) vaccine candidate and additional vaccine candidates. The Company’s COVID-19 Vaccine and its other vaccine candidates incorporate the Company’s proprietary Matrix-M™ adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.</span></div>
CY2024Q1	us-gaap	Translation Adjustment Functional To Reporting Currency Gain Loss Reclassified To Earnings Net Of Tax TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax	-5100000	usd
CY2023Q1	us-gaap	Translation Adjustment Functional To Reporting Currency Gain Loss Reclassified To Earnings Net Of Tax TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax	16300000	usd
CY2024Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	480600000	usd
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-147600000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-83600000	usd
CY2024Q1	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated Inception To Date Percent RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent	0.85
CY2024Q1	us-gaap	Severance Costs1 SeveranceCosts1	4400000	usd
CY2024Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	1700000	usd
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.</span></div>
CY2024Q1	us-gaap	Billed Contract Receivables BilledContractReceivables	21200000	usd
CY2023Q4	us-gaap	Billed Contract Receivables BilledContractReceivables	286400000	usd
CY2024Q1	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	200000	usd
CY2023Q4	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	10800000	usd
CY2023Q4	us-gaap	Accounts Receivable Gross AccountsReceivableGross	304916000	usd
CY2024Q1	nvax	Accounts Receivable Before Allowance For Credit Loss Additions AccountsReceivableBeforeAllowanceForCreditLossAdditions	136510000	usd
CY2024Q1	nvax	Accounts Receivable Before Allowance For Credit Loss Deductions AccountsReceivableBeforeAllowanceForCreditLossDeductions	412370000	usd
CY2024Q1	us-gaap	Accounts Receivable Gross AccountsReceivableGross	29056000	usd
CY2022Q4	us-gaap	Accounts Receivable Gross AccountsReceivableGross	96210000	usd
CY2023Q1	nvax	Accounts Receivable Before Allowance For Credit Loss Additions AccountsReceivableBeforeAllowanceForCreditLossAdditions	146424000	usd
CY2023Q1	nvax	Accounts Receivable Before Allowance For Credit Loss Deductions AccountsReceivableBeforeAllowanceForCreditLossDeductions	115950000	usd
CY2023Q1	us-gaap	Accounts Receivable Gross AccountsReceivableGross	126684000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	7676000	usd
CY2024Q1	nvax	Accounts Receivable Allowance For Credit Loss Additions AccountsReceivableAllowanceForCreditLossAdditions	0	usd
CY2024Q1	nvax	Accounts Receivable Allowance For Credit Loss Deductions AccountsReceivableAllowanceForCreditLossDeductions	0	usd
CY2024Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	7676000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	13835000	usd
CY2023Q1	nvax	Accounts Receivable Allowance For Credit Loss Additions AccountsReceivableAllowanceForCreditLossAdditions	0	usd
CY2023Q1	nvax	Accounts Receivable Allowance For Credit Loss Deductions AccountsReceivableAllowanceForCreditLossDeductions	0	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	13835000	usd
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	863521000	usd
CY2024Q1	nvax	Contract With Customer Liability Additions ContractWithCustomerLiabilityAdditions	225000000	usd
CY2024Q1	nvax	Contract With Customer Liability Deductions ContractWithCustomerLiabilityDeductions	6148000	usd
CY2024Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	1082373000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	549551000	usd
CY2023Q1	nvax	Contract With Customer Liability Additions ContractWithCustomerLiabilityAdditions	140324000	usd
CY2023Q1	nvax	Contract With Customer Liability Deductions ContractWithCustomerLiabilityDeductions	49000	usd
CY2023Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	689826000	usd
CY2023Q1	nvax	Accounts Receivable Allowance For Credit Loss Additions AccountsReceivableAllowanceForCreditLossAdditions	0	usd
CY2024Q1	nvax	Accounts Receivable Allowance For Credit Loss Additions AccountsReceivableAllowanceForCreditLossAdditions	0	usd
CY2024Q1	nvax	Contract With Customer Liability Additions ContractWithCustomerLiabilityAdditions	225000000	usd
CY2024Q1	nvax	Remaining Performance Obligation Amount RemainingPerformanceObligationAmount	2000000000	usd
CY2024Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	1100000000	usd
CY2024Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-3600000	usd
CY2024Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-3600000	usd
CY2024Q1	nvax	Amounts Charged Against Product Sales AmountsChargedAgainstProductSales	3400000	usd
CY2024Q1	nvax	Royalty Period RoyaltyPeriod	P15Y
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	480586000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	568505000	usd
CY2024Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	10455000	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	10424000	usd
CY2024Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	4895000	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	4881000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	495936000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	583810000	usd
CY2024Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	5295000	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	6614000	usd
CY2024Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	8984000	usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	7392000	usd
CY2024Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1499000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	27690000	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	15778000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	41696000	usd
CY2024Q1	us-gaap	Inventory Write Down InventoryWriteDown	8800000	usd
CY2023Q1	us-gaap	Inventory Write Down InventoryWriteDown	-12500000	usd
CY2023Q1	us-gaap	Inventory Firm Purchase Commitment Loss InventoryFirmPurchaseCommitmentLoss	-7700000	usd
CY2023Q1	nvax	Inventory Firm Purchase Commitment Recoveries InventoryFirmPurchaseCommitmentRecoveries	800000	usd
CY2024Q1	us-gaap	Number Of Reporting Units NumberOfReportingUnits	1	reporting_unit
CY2023	us-gaap	Number Of Reporting Units NumberOfReportingUnits	1	reporting_unit
CY2023Q4	us-gaap	Goodwill Goodwill	127454000	usd
CY2024Q1	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-4275000	usd
CY2024Q1	us-gaap	Goodwill Goodwill	123179000	usd
CY2024Q1	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	6818000	usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	7234000	usd
CY2024Q1	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	168432000	usd
CY2023Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	168016000	usd
CY2024Q1	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	2192000	usd
CY2023Q1	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	3206000	usd
CY2024Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	416000	usd
CY2023Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	510000	usd
CY2024Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	2608000	usd
CY2023Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	3716000	usd
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	11556000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	28647000	usd
CY2024Q1	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	0	usd
CY2023Q1	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	0	usd
CY2024Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	87000000	usd
CY2024Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	4500000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1500000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	100000	usd
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y1M6D
CY2024Q1	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	2300000	usd
CY2023Q1	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	1200000	usd
CY2022Q4	us-gaap	Loss Contingency Number Of Defendants LossContingencyNumberOfDefendants	2	defendant
CY2022Q4	nvax	Loss Contingency Period To Answer LossContingencyPeriodToAnswer	P14D
CY2023Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	47000000	usd
CY2024Q1	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	47000000	usd
CY2022Q4	us-gaap	Loss Contingency New Claims Filed Number LossContingencyNewClaimsFiledNumber	8	lawsuit
CY2024Q1	us-gaap	Severance Costs1 SeveranceCosts1	4401000	usd
CY2024Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	1669000	usd
CY2024Q1	us-gaap	Restructuring Charges RestructuringCharges	6070000	usd
CY2024Q1	nvax	Payments For Severance And Employee Benefit Costs PaymentsForSeveranceAndEmployeeBenefitCosts	3900000	usd
CY2024Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	1700000	usd
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001000694-24-000031-index-headers.html	Edgar Link	pending
0001000694-24-000031-index.html	Edgar Link	pending
0001000694-24-000031.txt	Edgar Link	pending
0001000694-24-000031-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
image_01a.jpg	Edgar Link	pending
image_02.jpg	Edgar Link	pending
image_0a.jpg	Edgar Link	pending
image_0b.jpg	Edgar Link	pending
image_1.jpg	Edgar Link	pending
image_11a.jpg	Edgar Link	pending
image_12.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nvax-20240331.htm	Edgar Link	pending
nvax-20240331.xsd	Edgar Link	pending
nvax-20240331xex311.htm	Edgar Link	pending
nvax-20240331xex312.htm	Edgar Link	pending
nvax-20240331xex321.htm	Edgar Link	pending
nvax-20240331xex322.htm	Edgar Link	pending
nvax-20240331xexhibit101.htm	Edgar Link	pending
nvax-20240331xexhibit102.htm	Edgar Link	pending
nvax-20240331xexhibit103.htm	Edgar Link	pending
nvax-20240331xexhibit104.htm	Edgar Link	pending
nvax-20240331_g1.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
nvax-20240331_def.xml	Edgar Link	unprocessable
nvax-20240331_lab.xml	Edgar Link	unprocessable
nvax-20240331_pre.xml	Edgar Link	unprocessable
nvax-20240331_htm.xml	Edgar Link	completed
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
nvax-20240331_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NVAX
NOVAVAX INC Stock $nvax

2024 Q2 Form 10-Q Financial Statement

#000100069424000031 Filed on May 10, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NVAX NOVAVAX INC Stock $nvax

2024 Q2 Form 10-Q Financial Statement

#000100069424000031 Filed on May 10, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NVAX
NOVAVAX INC Stock $nvax